Clinical trials · Missouri
HER2 + Breast Cancer clinical trials in Missouri
We’re tracking 66 recruiting her2 + breast cancer studies with a site in Missouri — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Missouri
- NCT07137416RecruitingPhase 1
Combination drug study for HER2-positive breast and other cancers
This study tests a new combination of two anti-cancer drugs (CX-5461 and T-DXd) for people with HER2-positive breast cancer or other solid tumors. It aims to see if the combination is safe and how well it works.
St Louis, MissouriAges 18 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Ballwin, MissouriAges 18 years+ - NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Kansas City, MissouriAges 18 years+ - NCT06590857RecruitingPhase 1/Phase 2
Study of targeted radiation for advanced breast cancer
This trial tests a new type of radiation therapy that targets a specific protein on some breast cancer cells. It may help people whose cancer has stopped responding to other treatments.
St Louis, MissouriAges Any age - NCT07578116RecruitingPhase 3
Adding surgery and radiation for her2-positive breast cancer with a few spread spots
This trial tests whether adding surgery and radiation to the usual HER2-targeted treatment helps people with breast cancer that has spread to a few spots. You must have HER2-positive cancer that is newly spread, and you must be able to receive radiation to all tumor sites.
Cape Girardeau, MissouriAges 18 years+ - NCT07383506RecruitingPhase 1
Study of a targeted pill for PIK3CA-mutated advanced cancers
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
St Louis, MissouriAges 18 years+ - NCT07368998RecruitingPhase 2
Study of inavolisib plus fulvestrant for advanced breast cancer
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
Kansas City, MissouriAges 18 years+ - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
St Louis, MissouriAges 18 years+ - NCT07220135RecruitingPhase 2
Comparing two drug combos before surgery for HER2+ breast cancer
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Kansas City, MissouriAges 18 years+ - NCT07211178Recruiting
Tracking cancer DNA in blood to detect early return of breast cancer
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
Springfield, MissouriAges 18–99 - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
St Louis, MissouriAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Kansas City, MissouriAges 18 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
St Louis, MissouriAges 18 years+ - NCT07007559RecruitingPhase 2
Evorpacept with trastuzumab and chemo for HER2-positive breast cancer
This study tests an experimental drug called evorpacept when given with trastuzumab and chemotherapy for people with HER2-positive breast cancer that has spread. The goal is to see if this combination can shrink tumors or slow down the cancer.
St Louis, MissouriAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
St Louis, MissouriAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Ballwin, MissouriAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Kansas City, MissouriAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Kansas City, MissouriAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Kansas City, MissouriAges 18 years+ - NCT06603597Recruiting
HER2-positive breast cancer registry
This registry tracks people with HER2-positive breast cancer to learn more about the disease and how it's treated. You can join at any stage of cancer.
Lee's Summit, MissouriAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant versus standard hormone therapy for early breast cancer
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
St Louis, MissouriAges 18 years+ - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Kansas City, MissouriAges 18 years+ - NCT06369285RecruitingPhase 2
Alisertib and hormone therapy for advanced breast cancer
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
Columbia, MissouriAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
St Louis, MissouriAges 18 years+
Where these studies are running in Missouri
Institutions with a site for the recruiting her2 + breast cancer studies listed above.
- Washington University in St. Louis · 7 studies
- Saint Luke's Hospital of Kansas City · 5 studies
- Saint Francis Medical Center · 3 studies
- Siteman Cancer Center at Washington University · 3 studies
- HCA Midwest Health · 2 studies
- KUCC - Lee's Summit · 2 studies
- Liberty Hospital · 2 studies
- Mercy Oncology and Hematology - Clayton-Clarkson · 2 studies
What taking part in a her2 + breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
HER2 + Breast Cancer trials in other states
Common questions
- Are there her2 + breast cancer clinical trials in Missouri?
- Yes. We're currently tracking 66 recruiting her2 + breast cancer studies with a site in Missouri, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a her2 + breast cancer study in Missouri?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Missouri to take part?
- Not necessarily. These studies have a site in Missouri, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New her2 + breast cancer studies open in Missouri regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.